Welcome to PracticeUpdate,

the FREE online resource exclusively for healthcare professionals.

Join Now for FREE

Our expert editorial boards review and hand-select specialty-specific clinical information from a variety of sources and add critical insights and context in these specialty areas:

Grid of PracticeUpdate Channels

Notice to Our Valued Users

Elsevier has made the difficult decision to close PracticeUpdate permanently. There will be no new content published, effective immediately. Although we are all disappointed by this news, we are incredibly grateful for your engagement and support over the years.

We thank the Editorial Boards, Advisory Boards, and Editorial Contributors for their many years of dedication to educating the healthcare community. Our appreciation extends to the many contributors who have shared their valuable time and expertise to help us parse the latest research over the years.

We encourage you to explore our other offerings such as ScienceDirect and ClinicalKey, which continue to provide valuable insights and information to help you excel in your practice.

If you have any questions or need assistance, please see the FAQs section or contact the support team. Thank you for being a part of the PracticeUpdate community!

Suggested Topics:

Multiple Myeloma

Renal Cell Carcinoma

Roger Stupp MD Advisory Board

Elizabeth Smyth MD Advisory Board

Lee S. Schwartzberg MD, FACP Advisory Board

See All Experts

Editor's Picks

featured

Ibrutinib for Early-Stage Chronic Lymphocytic Leukemia

J. Clin. Oncol · December 11, 2024
featured

IgG Testing, Immunoglobulin Replacement Therapy, and Infection Outcomes in CLL or NHL in the Real World

Blood Adv · September 04, 2024
featured

Acalabrutinib With or Without Obinutuzumab vs Zanubrutinib Monotherapy for Treatment-Naïve CLL Without Del(17p)

Blood Adv · May 19, 2024
featured

MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Relapsed CLL: Long-Term Efficacy and ctDNA Analysis

Blood · May 15, 2024

1 Expert Comment

updated
featured

Anti-CD19 CAR T-Cell Therapy for Richter Transformation

J. Clin. Oncol · May 09, 2024

1 Expert Comment

updated
featured

Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia

N. Engl. J. Med · February 13, 2024

1 Expert Comment

updated

Expert Opinion

featured

Ibrutinib and Venetoclax as Frontline Therapy for CLL

Interview · February 24, 2022
featured

Autoimmune Cytopenias and Treatment of CLL

Interview · February 24, 2022
featured

COVID-19 Vaccination in Patients With CLL

Interview · February 23, 2022
featured

Acalabrutinib vs Ibrutinib for Previously Treated CLL

Interview · February 23, 2022
featured

CLL and Hematopoietic Stem Cell Transplantation

Interview · December 14, 2021

Journal Scans

featured

Ibrutinib for Early-Stage Chronic Lymphocytic Leukemia

J. Clin. Oncol · December 11, 2024
Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL

Blood · October 30, 2024
Atezolizumab, Venetoclax, and Obinutuzumab for Richter Transformation DLBCL

Lancet Oncol · October 13, 2024
Third-Generation Anti-CD19 CAR T Cells for Relapsed/Refractory Chronic Lymphocytic Leukemia

Leukemia · October 05, 2024
Leukaemia, Lymphoma, and Multiple Myeloma Mortality After Low-Level Exposure to Ionising Radiation in Nuclear Workers

Lancet Haematol · September 29, 2024

News

Protracted Radiation Exposure Linked to Hematologic Cancer Mortality

HealthDay · October 28, 2024
Improved Outcomes Seen With Ibrutinib in Chronic Lymphocytic Leukemia

HealthDay · June 23, 2024
Ending Specialized Follow-Up Feasible in Asymptomatic, Low-Risk Leukemia

HealthDay · April 19, 2024
FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma

HealthDay · March 19, 2024
ASH 2023: Using Measurable Residual Disease to Guide Ibrutinib-Venetoclax Treatment Length Aids Outcomes in Chronic Lymphocytic Leukemia

PracticeUpdate Editorial Team · December 18, 2023

ASH

Meet Our Experts

PracticeUpdate is guided by a world-renowned Editorial and Advisory Board that represents community practitioners and academic specialists with cross-disciplinary expertise. View all boards

Cardiology

Douglas Zipes MD
Editor in Chief

Clinical Dentistry

Michael Newman DDS, FACD
Editor in Chief

Dermatology

Robert Brodell MD, FAAD
Editor in Chief

Diabetes

Silvio Inzucchi MD
Editor in Chief

Eye Care

Paul Freeman OD, FAAO, FOVDR
Editor in Chief

Eye Care

Myron Yanoff MD
Editor in Chief

Gastroenterology

Gail Hecht MD
Editor in Chief

Neurology

Mark Hallett MD
Editor in Chief

Oncology

Rafael Fonseca MD
Editor in Chief

Primary Care

David Rakel MD, FAAFP
Editor in Chief

Respiratory Medicine

Shyoko Honiden MD, MSc
Editor in Chief